Kostas Biliouris
Stock Analyst at BMO Capital
(1.19)
# 3,725
Out of 5,050 analysts
62
Total ratings
36.73%
Success rate
-13.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $50 | $17.63 | +183.61% | 9 | Sep 22, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $442.70 | +6.17% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $73.55 | -4.83% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $1.78 | +124.72% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.17 | +152.37% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $69.84 | +3.09% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $18.36 | +172.33% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $6.58 | +279.94% | 2 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $9.52 | +425.21% | 6 | Jan 10, 2025 | |
| DTIL Precision BioSciences | Upgrades: Outperform | $34 | $6.14 | +453.75% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $35 | $22.12 | +58.23% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $2.16 | +687.04% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $10.50 | +280.95% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $31.80 | +183.02% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $33.84 | +254.61% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $22.21 | +156.64% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $61.80 | -40.13% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $51.46 | +94.33% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $3.81 | +398.69% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $55.12 | +77.79% | 1 | Jun 17, 2022 |
Sarepta Therapeutics
Sep 22, 2025
Upgrades: Outperform
Price Target: $50
Current: $17.63
Upside: +183.61%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $442.70
Upside: +6.17%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $73.55
Upside: -4.83%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $1.78
Upside: +124.72%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.17
Upside: +152.37%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $69.84
Upside: +3.09%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $18.36
Upside: +172.33%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $6.58
Upside: +279.94%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $9.52
Upside: +425.21%
Precision BioSciences
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $6.14
Upside: +453.75%
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $22.12
Upside: +58.23%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $2.16
Upside: +687.04%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $10.50
Upside: +280.95%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $31.80
Upside: +183.02%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $33.84
Upside: +254.61%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $22.21
Upside: +156.64%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $61.80
Upside: -40.13%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $51.46
Upside: +94.33%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $3.81
Upside: +398.69%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $55.12
Upside: +77.79%